Review3 Biotech2023
Advances in the stimuli-responsive mesoporous silica nanoparticles as drug delivery system nanotechnology for controlled release and cancer therapy.
Review in 3 Biotech, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Endothelium-targeted and untargeted nanoparticle therapies in thromboinflammatory vascular diseases.Blood vessels, thrombosis & hemostasis · 2026Review
- Photoresponsive mesoporous silica nanocarriers for paraquat with substantially reduced acute toxicity and effective weed control.Pest management science · 2026Article
- Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance.Frontiers in oncology · 2026Review
- PD-L1 Aptamer-Functionalized Mesoporous Silica Nanoparticles for Targeted Doxorubicin Delivery in Triple-Negative Breast Cancer.International journal of nanomedicine · 2026Article
- Advances in Drug Delivery Systems for Breast Cancer: From Microenvironment Barriers and Smart Carriers to Clinical Translation Strategies.Drug design, development and therapy · 2026Review
- Enhancing Therapeutic Efficacy Through Tailored Pharmacokinetics: A Review of Mesoporous Silica Nanoparticle-Based Delivery Systems.International journal of nanomedicine · 2026Review
- Exosomes in cancer nanomedicine: biotechnological advancements and innovations.Molecular cancer · 2025Review
- Article
- Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer.International journal of nanomedicine · 2025Review
- Innovative applications of silicon dioxide nanoparticles for targeted liver cancer treatment.Frontiers in bioengineering and biotechnology · 2025Review
- Harnessing the power of thermosensitive liposomes with gold nanoprisms and silica for controlled drug delivery in combined chemotherapy and phototherapy.RSC advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesoporous silica nanoparticles (MSN) have attracted widespread attention in the field of drug delivery and biomedicine due to their unique structure and physicochemical properties. However, MSN still have shortcomings, such as premature drug release, poorly controlled release ability and poor targeting. Therefore, in order to reduce the damage of anti-cancer drugs to normal cells, improve their utilization rate and realize their selective release in tumor cells, "gated" stimuli-responsive mesoporous silicon nanomaterials as antitumor drug delivery carriers have attracted widespread interest among researchers. The "gated" stimuli-responsive nanovalves drug delivery system can only be removed under certain specific stimuli, which makes the drug maintain "zero release" before reaching the lesion site and achieve drug accumulation in tumor cells, effectively reducing the toxic and side effects on normal cells or tissues, and greatly exerting the efficacy of anti-cancer drugs. Therefore, the construction of stimuli-responsive nano-drug delivery systems have great application potential and significance in cancer treatment and controlled release of anti-cancer drugs. This review article emphasizes the research progress of the "gated" stimuli-responsive MSN (e.g. pH, redox potential, enzyme, temperature and light) or controlled drug release and cancer treatment since 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.